Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FX101
- Development stage
- Preclinical
- Lead developer
- Jericho Sciences
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FX101 is a preclinical-stage small molecule antiretroviral compound developed by Jericho Sciences. It is designed as a CNS-penetrating agent that modulates lipid rafts, caveolin proteins, and caveolar function. By targeting these membrane microdomains, FX101 aims to disrupt the viral life cycle of lentiviruses, including HIV-1, Simian Immunodeficiency Virus (SIV), and Feline Immunodeficiency Virus (FIV). Its ability to cross the blood-brain barrier is intended to address viral reservoirs in the central nervous system that are often poorly reached by standard antiretroviral therapies.
- Other names
- FX101FX-101FX 101
02
Targets
NC zinc finger (HIV-1 nucleocapsid CCHC zinc finger domain)
Beyond the preview
Go deeper on FX101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FX101.